Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Human cholangiocarcinoma LC-MS/MS

ABSTRACT: The glycosylation landscape of Human cholangiocarcinoma (CCA), and how it affects CCA diagnosis and prognosis, has recently emerged as an appealing research field.In this study, we used chemical glycoproteomic analysis Click-iG for systematic profiling of intact glycopeptides in CCA and HIBEpiC cell lines.

INSTRUMENT(S): Orbitrap Fusion Lumos

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Epithelial Cell, Cell Culture

DISEASE(S): Cholangiocarcinoma

SUBMITTER: xiangfeng Meng

LAB HEAD: Xiangfeng Meng

PROVIDER: PXD048188 | Pride | 2024-06-22

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	21-284_LJL0628_sample-HIBE-PG-1.raw	Raw
	21-284_LJL0628_sample-HIBE-PG-2.raw	Raw
	21-284_LJL0628_sample-HIBE-PG-3.raw	Raw
	21-284_LJL0628_sample-HU-PG-1.raw	Raw
	21-284_LJL0628_sample-HU-PG-2.raw	Raw

Items per page:

1 - 5 of 10

Publications

O-GlcNAcylation Facilitates the Interaction between Keratin 18 and Isocitrate Dehydrogenases and Potentially Influencing Cholangiocarcinoma Progression.

Meng Xiangfeng X Zhou Yue Y Xu Lei L Hu Limu L Wang Changjiang C Tian Xiao X Zhang Xiang X Hao Yi Y Cheng Bo B Ma Jing J Wang Lei L Liu Jialin J Xie Ran R

ACS central science 20240423 5

Glycosylation plays a pivotal role in the intricate landscape of human cholangiocarcinoma (CCA), actively participating in key pathophysiological processes driving tumor progression. Among the various glycosylation modifications, O-linked β-N-acetyl-glucosamine modification (O-GlcNAcylation) emerges as a dynamic regulator influencing diverse tumor-associated biological activities. In this study, we employed a state-of-the-art chemical proteomic approach to analyze intact gly ...[more]

PMID: 38799671

Similar Datasets

A Combinatorial Enzymatic Approach for Identifying O-glycopeptides

Project description:Proteins glycosylation is primarily characterized as N-glycosylation or O-glycosylation. Recognition of the consensus N-glycosylation sequon (N-X-S/T/C) has enabled the mapping of the glycosite occupancy of intact glycopeptides, whereas O-glycosylation consensus sequons do not exit, making the characterization of O-glycosites challenging because of the different degrees of occupancy within a protein. Most O-glycosylation occurs via O-GalNAcylation, which is critical to diverse biological functions. However, only a small fraction of the O-glycosites and their glycan structures have been identified. We introduced a robust and reliable O-glycoproteomic workflow to achieve the long-standing goal of glycobiology—identifying novel O-glycosylation profiles on a large-scale. We developed and implemented a novel O-glycoproteomic workflow through the use of complementary digestion with O-glycoprotease (IMPa), trypsin, Asp-N, and Glu-C for enrichment of O-glycopeptides. The N-terminal of O-glycosylated serine or threonine residues cleaved using IMPa (95% of total PSMs) and over 99% of O-glycopeptides were enriched by the RAX column. Our O-glycoproteomic workflow involving peptide identification (using sceHCD-based MS/MS) and annotation (using FDR evaluation) enabled the identification of O-glycosylation of 189 O-glycosites carrying 379 glycan structures on 79 O-glycoproteins in human plasma. Of the O-glycan forms, 91.7% were distinctively and abundantly observed in core 1 and 2 structures. Importantly, we assessed five well-characterized native proteins purified from human plasma (kininogen-1, fetuin-A, fibrinogen, apolipoprotein E, and plasminogen) to validate the identification of O-glycosites with high confidence and confirm the presence of numerous novel glycosites. We believe that this combinatorial approach is broadly applicable for comprehensive characterization of O-glycoproteomes in biomedical research.

2024-04-25 | PXD042701 | Pride

Re-analysis of glycoproteomics data with MSFragger-Glyco

Project description:Reanalysis of submissions PXD011533 and PXD009476 using MSFragger-Glyco mode. Processed MSFragger results files (pepXML) and PSM tables (psm.tsv) supporting MSFragger-Glyco manuscript (Fast and Comprehensive N- and O-glycoproteomics analysis with MSFragger-Glyco. Recent advances in methods for enrichment and mass spectrometric analysis of intact glycopeptides have produced large-scale glycoproteomics datasets, but interpreting this data remains challenging. We present MSFragger-Glyco, aa new glycoproteomics mode of the MSFragger search engine, called MSFragger-Glyco, for fast and sensitive identification of N- and O-linked glycopeptides and open glycan searches. Reanalysis of recent N-glycoproteomics data resulted in annotation of 80% more glycopeptide-spectrum matches (glycoPSMs) than previously reported. In published O-glycoproteomics data, our method more than doubled the number of glycoPSMs annotated when searching the same glycans as the original search and yielded 4-6-fold increases when expanding searches to include additional glycan compositions and other modifications. Expanded searches also revealed many sulfated and complex glycans that remained hidden to the original search.

2020-10-06 | PXD021196 | Pride

Site-Specific Glycosylation Analysis of Murine and Human Fcɣ Receptors IIA and IIB.

Project description:Site-specific glycosylation analysis by nLC-MS/MS of recombinant human Fcγ receptors IIA (H&R167 isoforms), IIB and murine Fcγ receptor IIB.

2024-08-10 | PXD049429 | Pride

Site-specific N-glycosylation analysis of recombinant FCγ receptor from human and mice.

Project description:Site-specific glycosylation analysis by nLC-MS/MS of recombinant human FCγ receptor I, III V158 and III 158F, and mouse FCγ receptor I, III and IV.

2024-05-21 | PXD043966 | Pride

An unusual dual sugar-binding lectin domain controls the substrate specificity of a mucin-type O-glycosyltransferase

Project description:N-acetylgalactosaminyl transferases (GalNAc-Ts) initiate mucin-type O-glycosylation, an abundant and complex post-translational modification that regulates host-microbe interactions, tissue development, and metabolism. GalNAc-Ts contain a C-terminal lectin domain consisting of three homologous repeats (, , where and can potentially interact with O-GalNAc on substrates to enhance activity towards a nearby acceptor Thr/Ser. The ubiquitous isoenzyme GalNAc-T1 modulates diverse biological functions, including heart development, immunity, and SARS-CoV-2 infectivity, but its substrates are largely unknown. Here, we show that both and in GalNAc-T1 uniquely orchestrate the O-glycosylation of various glycopeptide substrates. The repeat directs O-glycosylation to acceptor sites C-terminal to an existing GalNAc, while the repeat directs O-glycosylation to N-terminal sites. Additionally, GalNAc-T1 incorporates and binding into various substrate binding modes to cooperatively increase the specificity towards an intermediate acceptor site. Our studies highlight a unique mechanism by which dual lectin repeats expand substrate specificity and inform on identifying the biological substrates affected by disruptions in GalNAc-T1 function.

2024-05-23 | PXD047845 | Pride

An integrated strategy reveals complex glycosylation of erythropoi-etin using top-down and bottom-up mass spectrometry

Project description:The characterization of therapeutic glycoproteins is challenging due to the structural micro- and macro-heterogeneity of the protein glycosylation. This study presents an in-depth strategy for glycosylation analysis using first-generation erythropoietin (epoetin beta), including a developed top-down mass spectrometric workflow for N-glycan analysis, bottom-up mass spectrometric methods for site-specific N-glycosylation and a LC-MS approach for O-glycan identi-fication. Permethylated N-glycans, peptides and enriched glycopeptides of erythropoietin were analyzed by nanoLC-MS/MS and de-N-glycosylated erythropoietin was measured by LC-MS, enabling the qualitative and quantitative analysis of glycosylation and different glycan modifications (e.g., phosphorylation and O-acetylation). Extending the coverage of our newly developed Python script to phosphorylated N-glycans enabled the identification of 140 N-glycan compositions (237 N-glycan structures) from erythropoietin. The site-specificity of N-glycans was revealed at glycopeptide level by pGlyco software using different proteases. In total, 215 N-glycan compositions were identified from N-glycan and glycopeptide analysis. Moreover, LC-MS analysis of de-N-glycosylated erythropoietin species identified two different O-glycan compositions, based on the mass shifts between non-O-glycosylated and O-glycosylated species. This integrated strategy allows the in-depth glycosylation analysis of a therapeutic glycoprotein to understand its pharmacological properties and improving the manufacturing processes.

2021-06-14 | PXD024835 | Pride

Mouse glycoproteome: Kidney - pGlyco 2

Project description:Precise and large-scale characterization of glycoproteome is critical for understanding the biological functions of glycoproteins. Due to the complexity of glycosylation, the overall throughput, data quality and accessibility of site-specific glycosylation analysis are overwhelmingly lower than those of routine proteomic studies. Here, we introduce a workflow that robustly identifies intact glycopeptides at a proteome scale using stepped-energy mass-spectrometry (MS) and pGlyco 2.0, a dedicated search engine for large-scale glycopeptide analysis with comprehensive quality control (false discovery rate evaluation on the glycan, peptide and glycopeptide matches).

2017-10-12 | PXD005412 | Pride

Mouse glycoproteome: Heart - pGlyco 2

2017-09-11 | PXD005413 | Pride

Mouse glycoproteome - pGlyco 2

2017-10-11 | PXD005553 | Pride

Mouse glycoproteome: Brain - pGlyco 2

2017-10-11 | PXD005411 | Pride